Philip C. Mack

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Collin M. Blakely, Thomas B.K. Watkins, Wei Wu et al. · Nature Genetics · 2017 · 566 citations · Full text

Co-occurring Genetic Alterations, Oncology, Somatic Variant +10

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough et al. · Clinical Cancer Research · 2018 · 386 citations

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

Amir Goldkorn, Benjamin Ely, David I. Quinn et al. · Journal of Clinical Oncology · 2014 · 329 citations · Full text

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Ramesh K. Ramanathan, Chandra P. Belani, D. A. Singh et al. · Cancer Chemotherapy and Pharmacology · 2009 · 286 citations

Hepatology, Medicine, Biliary Cancer +9

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos et al. · Nature Medicine · 2015 · 275 citations · Full text

Ras-mapk Dependence Underlies, Eml4-alk–positive Lung Cancer, Medicine +11